Improving lipid control following myocardial infarction

Current Opinion in Cardiology

Volumn 29, Issue 5, 2014, Pages 454-466

  Ankam, Jyoti ^a   Feldman, David I ^a   Blaha, Michael J ^a   Martin, Seth S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

cholesterol; lipids; lipoproteins; myocardial infarction; secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

HUMAN; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; SECONDARY PREVENTION;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY AS TOPIC; PATIENT COMPLIANCE; SECONDARY PREVENTION;

EID: 84906054865     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000093     Document Type: Review

References (50)

1. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: Relationship with subclinical disease, undertreatment, and poor adherence: Implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 2013; 9:617-670.
2. Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: The treating to new targets (TNT) study. Circulation 2012; 125:1979-1987.
3. Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: What have we learned? Cardiovasc Diabetol 2014; 13:26.
4. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013; 13:S0735-1097; 06028-2. doi:10.1016/j.jacc.2013.11.002. [Epub ahead of print]
5. Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009; 54:2358-2362.
6. Hsu S, Ton VK, Dominique Ashen M, et al. A clinician's guide to the ABCs of cardiovascular disease prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clin Cardiol 2013; 36:383-393.
7. Martin SS, Blumenthal RS, Miller M. LDL cholesterol: The lower the better. Med Clin North Am 2012; 96:13-26.
8. Martin SS, Metkus TS, Horne A, et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol 2012; 110:307-313.
9. World Health Organization. Cardiovascular diseases: Fact sheet N8317. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/. [Accessed 26 March 2014]
10. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 2014; 129:399-410.
11. Ruiz-Bailen M, Romero-Bermejo FJ, Exposito-Ruiz M, et al. Early statin therapy in acute myocardial infarction (in Spanish). Med Intensiva 2014; 38:11-20.
12. Benjo AM, El-Hayek GE, Messerli F, et al. High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: A metaanalysis of randomized controlled trials. Catheter Cardiovasc Interv 2013; Nov 23. doi: 10.1002/ccd.25302. [Epub ahead of print]
13. Athyros VG, Katsiki N, Tziomalos K, et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: A post hoc analysis of the GREACE study. Arch Med Sci 2013; 9:418-426.
14. Cholesterol Treatment Trialists. Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
15. Macchia A, Romero M, D'Ettorre A, et al. Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: An observational retrospective study. PLoS One 2013; 8:e62772.
16. Toth PP, Foody JM, Tomassini JE, et al. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol 2014; 8:107-116.
17. Tenenbaum A, Medvedofsky D, Fisman EZ, et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute coronary syndrome Israeli Surveys data. PLoS One 2012; 7:e35298.
18. Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med 2013; 173:1808-1818.
19. Rauch B, Riemer T, Schwaab B, et al. Short-term comprehensive cardiac rehabilitation after AMI is associated with reduced 1-year mortality: Results from the OMEGA study. Eur J Prev Cardiol 2013; Apr 4. [Epub ahead of print]
20. Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol 2013; 7:484-525.
21. HPS2-THRIVE Investigators. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34:1279-1291.
22. AIM-HIGH Investigators. Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
23. Martin SS, Ou FS, Newby LK, et al. Patient-and trial-specific barriers to participation in cardiovascular randomized clinical trials. J Am Coll Cardiol 2013; 61:762-769.
24. Martin SS, Blumenthal RS. Concepts and controversies: The 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. Ann Intern Med 2014; 160:356-358.
25. Martin SS, Abd TT, Jones SR, et al. 2013 American cholesterol treatment guideline: What was done well and what could be done better. J Am Coll Cardiol 2014; 63:2674-2678.
26. Ton VK, Martin SS, Blumenthal RS, Blaha MJ. Comparing the new European cardiovascular disease prevention guideline with prior American Heart Association guidelines: An editorial review. Clin Cardiol 2013; 36:E1-6.
27. Anderson TJ, Gregoire J, Hegele RA, et al. Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. Can J Cardiol 2014; 30:377-380.
28. Ray KK, Kastelein JJ, Matthijs Boekholdt S, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35:960-968.
29. Martin SS, Gosch K, Kulkarni KR, et al. Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am Heart J 2013; 165:26-33.
30. Tattersall MC, Gangnon RE, Karmali KN, et al. Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: Longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys. PLoS One 2013; 8:e59309.
31. Hambraeus K, Lindhagen L, Tyden P, et al. Target-attainment rates of lowdensity lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in Sweden. Am J Cardiol 2014; 113:17-22.
32. Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013; 62:732-739.
33. Martin SS, BlahaMJ, Toth PP, et al. Very large database of lipids: Rationale and design. Clin Cardiol 2013; 36:641-648.
34. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013; 310:2061-2068.
35. Elshazly MB, Martin SS, Blaha MJ, et al. Nonhigh-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: The VLDL-2 study (very large database of lipids). J Am Coll Cardiol 2013; 62:1960-1965.
36. Desai NR, Choudhry NK. Impediments to adherence to post myocardial infarction medications. Curr Cardiol Rep 2013; 15:322.
37. Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013; 7:472-483.
38. Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation 2014; 129:1303-1309.
39. Pronovost PJ. Enhancing physicians' use of clinical guidelines. JAMA 2013; 310:2501-2502.
40. Aspry KE, Furman R, Karalis DG, et al. Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials. J Clin Lipidol 2013; 7:546-560.
41. Angeli F, Reboldi G, Mazzotta G, et al. Statins in acute coronary syndrome: Very early initiation and benefits. Ther Adv Cardiovasc Dis 2012; 6:163-174.
42. Blaha MJ, Martin SS. How do statins work?: Changing paradigms with implications for statin allocation. J Am Coll Cardiol 2013; 62:2392-2394.
43. Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link? J Am Coll Cardiol 2013; 62:397-408.
44. Berman JP, Farkouh ME, Rosenson RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs 2013; 18:193-205.
45. Laufs U, Weintraub WS, Packard CJ. Beyond statins: What to expect from add-on lipid regulating therapy? Eur Heart J 2013; 34:2660-2665.
46. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29:1553-1568.
47. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2013; 15:291.
48. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34:2949-3003.
49. Estruch R, Ros E. Eat a healthy diet and drink wisely to postpone dying if you survived a myocardial infarction?: Yes, but randomized clinical trials are needed. JAMA Intern Med 2013; 173:1819-1820.
50. Leon AS. Cardiac rehabilitation and secondary prevention after acute MI. In: Essential cardiology. New York: Springer; 2013. pp. 495-503